Non-Measurable Negotiations: The EU between Transnational Regulation of Pharmaceuticals and Private Law

Research output: Chapter in Book/Conference paperChapter

33 Downloads (Pure)

Abstract

The aims of this chapter are to look at the role of the EU in regulating pharmaceutical safety in the internal market, and to contrast that role with the EU’s peculiar capacity of co-regulator in the transnational space of pharmaceutical safety and efficacy governance. The intent of the analysis proposed in this piece is to highlight a dichotomy between the internal and external roles of the EU in the pharmaceutical rule-making arena. Whereas throughout the second half of the 20th century the EU has gained internally an ever more prominent and centralized role in the regulation of medicines, culminating with the adoption of Directive 2001/83/EC on the Community Code relating to medicinal products for human use (and subsequent amendments and addenda), externally the situation is one of significant complexity. The intricacies of the transnational institutional framework of pharmaceutical regulation need to be addressed and described in order to propose an understanding of the regulatory role for the traditional private law dimension. What is contended here is that while a form of ‘regulatory private law’ has been developing at a transnational level with intrinsic limits (what will be referred to as ‘non-measurable negotiations’), traditional forms of private law have the potential to vindicate a significant role in guiding the EU as a negotiator in the transnational ‘regulatory private law-making’.
Original languageEnglish
Title of host publicationPrivate Law in the External Relations of the EU
EditorsMarise Cremona, Hans-W Micklitz
Place of PublicationUnited Kingdom
PublisherOxford University Press
Chapter12
Pages273-296
ISBN (Print)9780198744566
DOIs
Publication statusPublished - 2016
Externally publishedYes

Fingerprint

private law
pharmaceutical
EU
regulation
European Community
amendment
medicine
governance
market
community

Cite this

Rizzi, M. (2016). Non-Measurable Negotiations: The EU between Transnational Regulation of Pharmaceuticals and Private Law. In M. Cremona, & H-W. Micklitz (Eds.), Private Law in the External Relations of the EU (pp. 273-296). United Kingdom: Oxford University Press. https://doi.org/10.1093/acprof:oso/9780198744566.003.0013
Rizzi, Marco. / Non-Measurable Negotiations : The EU between Transnational Regulation of Pharmaceuticals and Private Law. Private Law in the External Relations of the EU. editor / Marise Cremona ; Hans-W Micklitz. United Kingdom : Oxford University Press, 2016. pp. 273-296
@inbook{1e5e8f94d2194db4b36047a5d70532a4,
title = "Non-Measurable Negotiations: The EU between Transnational Regulation of Pharmaceuticals and Private Law",
abstract = "The aims of this chapter are to look at the role of the EU in regulating pharmaceutical safety in the internal market, and to contrast that role with the EU’s peculiar capacity of co-regulator in the transnational space of pharmaceutical safety and efficacy governance. The intent of the analysis proposed in this piece is to highlight a dichotomy between the internal and external roles of the EU in the pharmaceutical rule-making arena. Whereas throughout the second half of the 20th century the EU has gained internally an ever more prominent and centralized role in the regulation of medicines, culminating with the adoption of Directive 2001/83/EC on the Community Code relating to medicinal products for human use (and subsequent amendments and addenda), externally the situation is one of significant complexity. The intricacies of the transnational institutional framework of pharmaceutical regulation need to be addressed and described in order to propose an understanding of the regulatory role for the traditional private law dimension. What is contended here is that while a form of ‘regulatory private law’ has been developing at a transnational level with intrinsic limits (what will be referred to as ‘non-measurable negotiations’), traditional forms of private law have the potential to vindicate a significant role in guiding the EU as a negotiator in the transnational ‘regulatory private law-making’.",
author = "Marco Rizzi",
year = "2016",
doi = "10.1093/acprof:oso/9780198744566.003.0013",
language = "English",
isbn = "9780198744566",
pages = "273--296",
editor = "Marise Cremona and Hans-W Micklitz",
booktitle = "Private Law in the External Relations of the EU",
publisher = "Oxford University Press",
address = "United Kingdom",

}

Rizzi, M 2016, Non-Measurable Negotiations: The EU between Transnational Regulation of Pharmaceuticals and Private Law. in M Cremona & H-W Micklitz (eds), Private Law in the External Relations of the EU. Oxford University Press, United Kingdom, pp. 273-296. https://doi.org/10.1093/acprof:oso/9780198744566.003.0013

Non-Measurable Negotiations : The EU between Transnational Regulation of Pharmaceuticals and Private Law. / Rizzi, Marco.

Private Law in the External Relations of the EU. ed. / Marise Cremona; Hans-W Micklitz. United Kingdom : Oxford University Press, 2016. p. 273-296.

Research output: Chapter in Book/Conference paperChapter

TY - CHAP

T1 - Non-Measurable Negotiations

T2 - The EU between Transnational Regulation of Pharmaceuticals and Private Law

AU - Rizzi, Marco

PY - 2016

Y1 - 2016

N2 - The aims of this chapter are to look at the role of the EU in regulating pharmaceutical safety in the internal market, and to contrast that role with the EU’s peculiar capacity of co-regulator in the transnational space of pharmaceutical safety and efficacy governance. The intent of the analysis proposed in this piece is to highlight a dichotomy between the internal and external roles of the EU in the pharmaceutical rule-making arena. Whereas throughout the second half of the 20th century the EU has gained internally an ever more prominent and centralized role in the regulation of medicines, culminating with the adoption of Directive 2001/83/EC on the Community Code relating to medicinal products for human use (and subsequent amendments and addenda), externally the situation is one of significant complexity. The intricacies of the transnational institutional framework of pharmaceutical regulation need to be addressed and described in order to propose an understanding of the regulatory role for the traditional private law dimension. What is contended here is that while a form of ‘regulatory private law’ has been developing at a transnational level with intrinsic limits (what will be referred to as ‘non-measurable negotiations’), traditional forms of private law have the potential to vindicate a significant role in guiding the EU as a negotiator in the transnational ‘regulatory private law-making’.

AB - The aims of this chapter are to look at the role of the EU in regulating pharmaceutical safety in the internal market, and to contrast that role with the EU’s peculiar capacity of co-regulator in the transnational space of pharmaceutical safety and efficacy governance. The intent of the analysis proposed in this piece is to highlight a dichotomy between the internal and external roles of the EU in the pharmaceutical rule-making arena. Whereas throughout the second half of the 20th century the EU has gained internally an ever more prominent and centralized role in the regulation of medicines, culminating with the adoption of Directive 2001/83/EC on the Community Code relating to medicinal products for human use (and subsequent amendments and addenda), externally the situation is one of significant complexity. The intricacies of the transnational institutional framework of pharmaceutical regulation need to be addressed and described in order to propose an understanding of the regulatory role for the traditional private law dimension. What is contended here is that while a form of ‘regulatory private law’ has been developing at a transnational level with intrinsic limits (what will be referred to as ‘non-measurable negotiations’), traditional forms of private law have the potential to vindicate a significant role in guiding the EU as a negotiator in the transnational ‘regulatory private law-making’.

U2 - 10.1093/acprof:oso/9780198744566.003.0013

DO - 10.1093/acprof:oso/9780198744566.003.0013

M3 - Chapter

SN - 9780198744566

SP - 273

EP - 296

BT - Private Law in the External Relations of the EU

A2 - Cremona, Marise

A2 - Micklitz, Hans-W

PB - Oxford University Press

CY - United Kingdom

ER -

Rizzi M. Non-Measurable Negotiations: The EU between Transnational Regulation of Pharmaceuticals and Private Law. In Cremona M, Micklitz H-W, editors, Private Law in the External Relations of the EU. United Kingdom: Oxford University Press. 2016. p. 273-296 https://doi.org/10.1093/acprof:oso/9780198744566.003.0013